Jeffrey Edward Watkins

US Patent:

7553489, Jun 30, 2009

Filed:

Dec 20, 2006

Appl. No.:

11/643982

Inventors:

James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitas CA, US
Herren Wu - Germantown MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/42
A61K 39/155

US Classification:

4241591, 4242111

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis of a RSV infection.

US Patent:

7847082, Dec 7, 2010

Filed:

Jun 1, 2009

Appl. No.:

12/476183

Inventors:

James F. Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie S. Johnson - Germantown MD, US
William D. Huse - Del Mar CA, US
Jeffrey D. Watkins - Encinitas CA, US
Herren Wu - Boyds MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

C07H 21/04
A61K 39/42
A61K 39/155

US Classification:

536 2353, 4241591, 4242111

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

US Patent:

20050147616, Jul 7, 2005

Filed:

Oct 8, 2004

Appl. No.:

10/962285

Inventors:

James Young - Potomac MD, US
Scott Koenig - Rockville MD, US
Leslie Johnson - Germantown MD, US
William Huse - Del Mar CA, US
Jeffrey Watkins - Encinitas CA, US
Herren Wu - Boyds MD, US

International Classification:

A61K039/42
C12Q001/70
C07H021/04
C12N005/06
C07K016/08

US Classification:

424159100, 435005000, 435069100, 435320100, 435339000, 530388300, 536023530

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection

US Patent:

20120070447, Mar 22, 2012

Filed:

Oct 18, 2010

Appl. No.:

12/906948

Inventors:

JAMES F. YOUNG - POTOMAC MD, US
SCOTT KOENIG - ROCKVILLE MD, US
LESLIE S. JOHNSON - GERMANTOWN MD, US
WILLIAM D. HUSE - DEL MAR CA, US
JEFFREY D. WATKINS - ENCINITAS CA, US
HERREN WU - BOYDS MD, US

Assignee:

MEDIMMUNE, LLC - GAITHERSBURG MD

International Classification:

A61K 39/42
C12N 15/13
C07K 16/46
A61P 31/14
C12N 1/21
C12N 5/10
C12P 21/00
C12Q 1/70
C12N 1/19
C07K 16/10
C12N 15/63

US Classification:

4241591, 5303894, 536 2353, 5303873, 4353201, 435339, 435 696, 435 5, 435419, 4352542, 4352523

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection